SecBot SecBot
SECBOTREPLAY Home › Report › LGND

LGND · Jason Aryeh, a director of Ligand Pharmaceuticals, filed a Form 144…

LIGAND PHARMACEUTICALS INC · 144 filed Nov 2, 2026 at 16:26 ET

At the news

NEUTRALIMPACT 2/10

144 filed Nov 2, 2026 at 16:26 ET

Jason Aryeh, a director of Ligand Pharmaceuticals, filed a Form 144 notice of intent to sell 700 shares of Class B common stock, with an approximate market value of $221,595. The shares were acquired between May and July 2019 via secondary market purchases. The sale is small relative to the company's $6.3B market cap and the insider's likely total holdings, making it a routine diversification move.

  • Jason Aryeh, a director, filed Form 144 to sell 700 shares of Class B common stock.
  • Estimated proceeds of $221,595 based on filing date price.
  • Shares were acquired between May 14, 2019 and July 30, 2019 via secondary market purchases.
  • The sale represents a tiny fraction of the company's $6.3B market cap.

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access